Evaluating radiotherapy for tumors in the thoracic region
Radiotherapy Treatments for the Treatment of Thoracic District Tumors
European Institute of Oncology · NCT06335290
This study is testing how well different types of radiotherapy work for patients with tumors in the chest area to find the best treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 13200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology (other) |
| Locations | 1 site (Milan) |
| Trial ID | NCT06335290 on ClinicalTrials.gov |
What this trial studies
This study evaluates the clinical and dosimetric aspects, tolerance, and effectiveness of radiotherapy treatments for patients with primary or secondary tumors located in the thoracic area. It aims to collect data from patients undergoing radiotherapy, which will help identify the best treatment strategies based on disease characteristics, patient preferences, and treatment outcomes. The study involves a multidisciplinary approach to treatment planning and aims to enhance understanding of how different radiotherapy techniques impact patient tolerance and effectiveness over time.
Who should consider this trial
Good fit: Ideal candidates include patients receiving radiotherapy for thoracic primary or secondary tumors, including various types of cancers affecting the thoracic region.
Not a fit: Patients receiving radiotherapy for tumors located outside the thoracic region will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with thoracic neoplasms, enhancing their tolerance and effectiveness of radiotherapy.
How similar studies have performed: Other studies have shown success in evaluating radiotherapy for thoracic tumors, but this study aims to provide a more comprehensive dataset for future treatment optimization.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the thoracic region include those with: * Primary bone tumors, * Primary soft tissue tumors, * Primary tumors of the cardio-circulatory system, * Primary tumors of the lymphatic system, * Primary tumors of the nervous system and skin, * Secondary metastases from various origins localized in the thoracic region. 2. Signed informed consent Exclusion Criteria: 1. Radiotherapy in districts other than the thoracic region.
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Barbara Alicja Jereczek — European Institute of Oncology
- Study coordinator: Barbara Alicja Jereczek
- Email: barbara.jereczek@ieo.it
- Phone: +39 02 57489326
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thoracic Neoplasms